Abstracts (HTML) List of Authors

Abel, P

Intravenöse Prostanoidtherapie der PAH – Zwischenfälle im Rahmen der Befüllung von implantierten Medikamentenpumpen – zwei Fallberichte

Aberer, E

Does anti-acid treatment influence disease progression in SSc-ILD? Data form the German SSc-network
Long term outcomes of immunmodulatory drugs in SSc-ILD – data rom the German SSc network

Ahluwalia, N

An Open-Label Extension (OLE) study of Tezacaftor/Ivacaftor (TEZ/IVA) in patients (PTS) ≥ 12 years with cystic fibrosis (CF) Homozygous for F508DEL-CFTR (F/F) or Heterozygous for F508DEL-CFTR and a residual function mutation (F/RF)

Ahn, JC

PD-L1-Expression im Primärtumor vs. Metastase in Proben der Phase-III-Studie MYSTIC bei 1st-Line metastasiertem NSCLC

Ahn, JS

ALINA: a phase III study of alectinib versus chemotherapy as adjuvant therapy in patients with stage IB-IIIA anaplastic lymphoma kinase-positive (ALK +) non-small cell cancer (NSCLC)

Ahn, M

Mutationen sind assoziiert mit einer Sensitivität oder Resistenz gegenüber einer Immuntherapie beim metastasierten NSCLC: eine Analyse aus der MYSTIC-Studie

Ahn, MJ

First-Line Therapy Using Brigatinib vs. Crizotinib in Patients With Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Results From a Phase 3 Trial

Ahrens, W

Kumulative Gefahrstoffexpositionen beim Schweißen und dessen Auswirkungen auf das Lungenkrebsrisiko

Akewanlop, C

Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter Tumorresektion

Akil, A

Frühe postoperative Reduktion des systolischen pulmonal arteriellen Druckes nach chirurgischer Lungenvolumenreduktion bei Patienten mit pulmonal arterieller Hypertonie

Akin, I

Durchführbarkeit und Anwendungsgebiete des multiple breath washout-Verfahrens (MBW) bei erwachsenen Patienten mit Asthma bronchiale

Akmatov, M

Zeitliche Trends und räumliche Variationen der Diagnoseprävalenz der COPD in Deutschland

Albers, FC

Effectiveness and safety of mepolizumab in real-world clinical practice: The REALITI-A study
Long-term safety and durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX

Alhasan, M

Maternal asthma is associated with persistent changes in allergic offspring antibody glycosylation
Administering antibiotics during pregnancy increases offspring asthma severity in a dose-dependent manner

Aliberti, S

Erstnachweis von nichttuberkulösen Mykobakterien bei Patienten mit Bronchiektasen-Erkrankung – Daten aus dem europäischen Bronchiektasen-Register EMBARC

Alisch, D

Function of the olfactory receptor OR2AT4 in alveolar macrophages

Alpay, N

Veränderung der Lungenfunktion während Platin-haltiger Chemotherapie bei Lungenkarzinom

Alshut, R

Untersuchung der Übereinstimmung der Ereigniserkennung von CPAP Geräten mit der Polysomnographie

Alt, J

CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)

Alter, P

The association of cognitive functioning as measured by the DemTect with clinical and functional characteristics of COPD
The impact of COPD on polyneuropathy: results from the German COPD cohort COSYCONET
CAT score single item analysis in patients with COPD: results from COSYCONET

Alves, M

Dose adjustments in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*
Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS Trial*
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial*
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial*
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*

Amann, D

Der chronische Intensivpatient: Demografie und Outcome

Amelina, E

Vergleich der Surrogatmarker (BMI, FEV1, Notwendigkeit einer i. v. Antibiotikatherapie) von CF-Patienten mit und ohne P.-aeruginosa-Infektion in Frankfurt und Moskau zwischen 1990 und 2015

Amin, N

Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Asthma and Serologic Evidence of Allergic Bronchopulmonary Aspergillosis
Dupilumab Effect on Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma with an Allergic Phenotype

Anaev, E

Eiweißmarker im Atemkondensat für Differentialdiagnose bei COPD und Asthma

Andreas, S

Abscopal effect in lung cancer: three case reports and a concise review

Anduleit, N

Prospektive Evaluation funktioneller Unterschiede bei Patienten mit adipositasassoziierten Atmungsstörungen
Pulmonary Hypertension in COPD: Is it worth looking for?
Ein pulmonalarterieller Wedgedruck von 21 mmHg unter Belastung trennt prä- und postkapilläre pulmonale Hypertonie unter Belastung

Angenendt, A

Role for the PD-1/PD-L1 axis in the development of COPD

Angenendt, S

Sensitivität und Spezifität EBUS/PET-Ct/Operation bei N2-Status – retrospektive 1-Jahres-Single-Center-Analyse

Armstrong, J

CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)

Arnold, P

Letermovir for difficult to treat cytomegalovirus infection in lung transplant recipients

Articus, K

Canopy-1: Phase 3 Study of Canakinumab/Placebo + Pembrolizumab + Platinum-chemotherapy in Untreated Stage III b-IV NSCLC pts

Artmann, M

Das Birt-Hogg-Dubé-Syndrom – eine potentielle „Blick“-Diagnose

Assassi, S

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*

Atug, E

Eine seltene Ursache für das Platypnoe-Orthodeoxie-Syndrom

auf dem Brinke, K

Surface proteome of plasma extracellular vesicles as biomarkers for pneumonia and acute exacerbation of COPD

Aumiller, J

EBUS-Angiographie (EBUS-A): Darstellung der Anatomie und pathologischen Befunde am Mediastinum und Hilus
CTEPH und Chronic Thromboembolic Disease (CTED): Primärdiagnose mit EBUS-Angiographie (EBUS-A)

Aurivillius, M

Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD
Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler, formulated using co-suspension delivery technology, improves lung function and exacerbation outcomes in patients with COPD without a recent history of exacerbations: subgroup analysis of KRONOS study

Austin, D

Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects

Azuma, A

Dose adjustments in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*
Changes in FVC in the SENSCIS Trial of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD)*
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing FVC at baseline: the SENSCIS Trial*
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): the SENSCIS trial*
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial*